Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However ...

They tend to be slow growing (indolent). The cells in these lymphomas look small under the microscope. There are 3 main types of marginal zone lymphomas: Extranodal marginal zone B-cell lymphoma, also ...

Objective The role of neutrophils in driving pathogenic B cell responses in SLE is not fully understood. In this study, we explored the link between immune complex (IC)–driven neutrophil activation, ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. As part of Genentech’s ...

The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated ...

The presence of lymphoma can worsen liver damage in PBC and significantly accelerate the progression of liver disease.

Enzyme identified as an important tumor inhibitor in T-cell lymphomas HDAC1 shows protective function against tumor growth Date: May 15, 2025 Source: Medical University of Vienna Summary ...

Anaplastic large cell lymphomas are rare but aggressive T-cell lymphomas. About 60%–80% of cases carry a gene fusion of the ALK gene, which drives tumor growth .

You see it in marginal zone lymphoma, follicular lymphoma, CLL, mantle cell and diffuse large B cell lymphoma. “We focused initially on DLBCL and mantle because those are ones where there’s a ...

In people with relapsing forms of multiple sclerosis (MS) treated with Ocrevus (ocrelizumab), levels of B-cells can help to predict the risk of progression independent of relapse activity ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...